Accordingly, transgenic PTX3 overexpression by tumor cells efficaciously impairs the activation of the FGF/FGFR system in FGF-driven tumor cell lines, thus affecting tumor growth and metastasis in different models of melanoma, prostate and mammary carcinomas (18–20). Here, PTX3 is linked to breast carcinoma.